MedTrace Logo

AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis

NCT00941031 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 404

Last updated 2015-08-20

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent to which the patient's body area is affected by the disease (compared to placebo).

Conditions

  • Chronic Plaque-type Psoriasis

Interventions

DRUG

AIN457

DRUG

AIN457A

Induction with monthly injections - "Monthly": secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 5, 9

DRUG

AIN457A

Early loading induction - "Early": secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 2, 3, 5

DRUG

Placebo

Placebo - "Placebo": Placebo administered at weeks 1, 2, 3, 5, 9

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • United States
  • France
  • Germany
  • Iceland
  • Israel
  • Japan
  • Norway

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00941031 on ClinicalTrials.gov